BioNumerik Launches Phase III Trial To Confirm Surprising Tavocept Survival Benefit In NSCLC
This article was originally published in The Pink Sheet Daily
Executive Summary
Meta-analysis of secondary endpoint data from earlier chemoprotection trials revealed as much as 6.7 months survival benefit compared to one or two months with current regimens.
You may also be interested in...
BioNumerik’s Tavocept Fails In Neuropathy, Adds To Survival Time
Firm is looking for commercialization partner for cancer candidates, CEO tells “The Pink Sheet” DAILY.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.